Abstract 2485
Background
Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality. This study focused on identification of RNA-Seqexpressionsignature for prognosis prediction of Uterine Sarcoma.
Methods
We obtained RNA-Seqexpression profiles from The Cancer Genome Atlas (TCGA) database and differential expressed genes (DEGs) were identified between US tissues and normal tissues. Univariate Cox proportional hazards regression analysis was performed to identify Prognosis associated DEGscorrelated with survival of US patients.The RNA-Seqbased prognostic signature was identified by least absolute shrinkage and selection operator (LASSO) Cox model. The cohort was randomly divided into training and testing groups. Thebiological pathway and processof putative RNA targets was also analyzed by bioinformatics.
Results
This study identified a RNA-Seq signature based on 11 genes, AP000320.1, HNRNPA1P33, RPL21P10, AC067773.1, AC011933.3, STX19, AC091133.4, HIST1H3A, AC004988.1, AL356585.1 and HNRNPA3P1. In the training group, the median OS in the high-risk and low-risk groups were 13.7 vs 88.1 months (HR, 0.204, 95% CI, 0.08589 - 0.4846; P < 0.0001), respectively. In the testing group, the median OS in the high-risk and low-risk groups were 11.9 vs 67.2 months (HR, 0.04315, 95% CI, 0.004845 - 0.3842; P < 0.0001) respectively. Genes in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis, which suggested that these genes might contribute to cancer-associated processes such as the nuclear nucleosome and DNA packaging complex.
Conclusions
This 11-genebased prognostic signature may improve prognosis prediction of US.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Linguistic correction
Resources from the same session
4413 - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Presenter: Ghassan Abou-Alfa
Session: Poster Display session 2
Resources:
Abstract
4710 - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Lorenza Rimassa
Session: Poster Display session 2
Resources:
Abstract
5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)
Presenter: Li-Tzong Chen
Session: Poster Display session 2
Resources:
Abstract
1463 - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Presenter: Sylvie Lorenzen
Session: Poster Display session 2
Resources:
Abstract
2392 - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2⁺/HER2⁻ Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Manish Shah
Session: Poster Display session 2
Resources:
Abstract
5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
Presenter: Rosine Guimbaud
Session: Poster Display session 2
Resources:
Abstract
1726 - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Presenter: Kenro Hirata
Session: Poster Display session 2
Resources:
Abstract
2279 - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Presenter: Shun Yamamoto
Session: Poster Display session 2
Resources:
Abstract
4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Jiafu Ji
Session: Poster Display session 2
Resources:
Abstract
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract